Published in AIDS Weekly, October 24th, 2005
"The first trial of the efficacy of a human immunodeficiency virus (HIV)-1 vaccine was conducted in North America and the Netherlands between 1998 and 2003. This multicenter, randomized, placebo-controlled trial of a recombinant glycoprotein 120 vaccine included 5,403 initially HIV-negative volunteers who were monitored for 3 years," investigators in the United States and Canada report.
"The 368 subjects who acquired HIV-1 infection were monitored for 2 years by use of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.